Skip to content

Adamas Pharmaceuticals, Inc.

CIK 0001328143

← back to feed
Revenue (TTM)
$87.36M
+355.5% YoY Q3 Oct 2021
Net Income (TTM)
−$56.35M
−148.8% YoY Q3 Oct 2021
EPS Diluted (TTM)
−$1.49
−377.6% YoY Q3 Oct 2021
Gross Margin
18.2%
Q3 Oct 2021
Operating Margin
-37.9%
Q3 Oct 2021
Net Margin
-64.5%
Q3 Oct 2021
Free Cash Flow (TTM)
−$84.97M
Q3 Oct 2021
Cash
$78.62M
Q3 Oct 2021
Total Debt
$129.04M
Q3 Oct 2021
Shares Outstanding
45.79M sh
Q3 Oct 2021

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings